As selective action towards US28 is a perquisite to avoid side effects from inadvertent killing of CX3CR1-expressing cells, the prototype F49A-FTP still presents the best candidate therapeutic to treat HCMV infections. This evidence concerns the gene CX3CR1 and cytomegalovirus infection.